1616340-47-6

Basic information

• Product Name: (1R,3S,4S,12aS)-3-fluoro-7-hydroxy-6,8-dioxo-N-(2,4,6-trifluorohenzyl)-1,2,3,4,6,8,12,12a-octahydro-1,4-methanodipyrido[1,2-a:1',2'-d]pyrazine-9-carboxamide
• Synonyms: (1R,3S,4S,12aS)-3-fluoro-7-hydroxy-6,8-dioxo-N-(2,4,6-trifluorohenzyl)-1,2,3,4,6,8,12,12a-octahydro-1,4-methanodipyrido[1,2-a:1',2'-d]pyrazine-9-carboxamide
• CAS NO: 1616340-47-6
• Molecular Weight: 451.377
• Mol File: 1616340-47-6.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: (1R,3S,4S,12aS)-3-fluoro-7-hydroxy-6,8-dioxo-N-(2,4,6-trifluorohenzyl)-1,2,3,4,6,8,12,12a-octahydro-1,4-methanodipyrido[1,2-a:1',2'-d]pyrazine-9-carboxamide(CAS DataBase Reference)
• NIST Chemistry Reference: (1R,3S,4S,12aS)-3-fluoro-7-hydroxy-6,8-dioxo-N-(2,4,6-trifluorohenzyl)-1,2,3,4,6,8,12,12a-octahydro-1,4-methanodipyrido[1,2-a:1',2'-d]pyrazine-9-carboxamide(1616340-47-6)
• EPA Substance Registry System: (1R,3S,4S,12aS)-3-fluoro-7-hydroxy-6,8-dioxo-N-(2,4,6-trifluorohenzyl)-1,2,3,4,6,8,12,12a-octahydro-1,4-methanodipyrido[1,2-a:1',2'-d]pyrazine-9-carboxamide(1616340-47-6)

Safety Data

• Hazardous Substances Data: 1616340-47-6(Hazardous Substances Data)

Upstream product

• 1616341-72-0 C₁₆H₂₁NO₃ 
• 130194-96-6 (1S,3S,4R)-2-[(1R)-1-phenylethyl]-2-azabicyclo[2.2.1]hept-5-ene-3-carboxylic acid methyl ester 
• 1616342-35-8 C₂₁H₁₉FN₂O₅ 
• 1616341-39-9 C₂₈H₂₃F₄N₃O₄ 
• 1616341-38-8 C₂₃H₂₃FN₂O₅ 
• 1616341-37-7 C₃₀H₃₇FN₂O₈ 
• 1616341-36-6 C₁₂H₂₁FN₂O₂ 
• 1616341-35-5 C₂₀H₂₃FN₂O₄ 
• 1616341-34-4 C₁₂H₂₀FNO₃ 
• 1616341-33-3 C₁₃H₂₀FNO₄ 
• 851389-58-7 2-tert-butyl 3-methyl (1R,3S,4S,6R)-6-hydroxy-2-azabicyclo[2.2.1]heptane-2,3-dicarboxylate 

Relevant articles and documents

POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE

Compounds for use in the treatment of human immunodeficiency virus (HIV) infection are disclosed. The compounds have the following Formula (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1, X, W, Y1, Y2, Ζ1 and Z4 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.